Hepatic (Liver) Metastasis - Pipeline Review, H2 2015

Published: Oct, 2015 | Pages: 68 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hepatic (Liver) Metastasis - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Hepatic (Liver) Metastasis - Pipeline Review, H2 2015', provides an overview of the Hepatic (Liver) Metastasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hepatic (Liver) Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatic (Liver) Metastasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hepatic (Liver) Metastasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Hepatic (Liver) Metastasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Hepatic (Liver) Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hepatic (Liver) Metastasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hepatic (Liver) Metastasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hepatic (Liver) Metastasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents
 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Hepatic (Liver) Metastasis Overview 8
Therapeutics Development 9
Pipeline Products for Hepatic (Liver) Metastasis - Overview 9
Pipeline Products for Hepatic (Liver) Metastasis - Comparative Analysis 10
Hepatic (Liver) Metastasis - Therapeutics under Development by Companies 11
Hepatic (Liver) Metastasis - Therapeutics under Investigation by Universities/Institutes 12
Hepatic (Liver) Metastasis - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Hepatic (Liver) Metastasis - Products under Development by Companies 15
Hepatic (Liver) Metastasis - Products under Investigation by Universities/Institutes 16
Hepatic (Liver) Metastasis - Companies Involved in Therapeutics Development 17
Amgen Inc. 17
BioCancell Ltd 18
CytRx Corporation 19
Digna Biotech, S.L. 20
Gradalis Inc. 21
Incuron, LLC 22
Novartis AG 23
Phosplatin Therapeutics LLC 24
Targetome 25
Hepatic (Liver) Metastasis - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
Antibodies to Inhibit FRMD4A for Oncology - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
BC-821 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
cancer vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Cell Therapy to Target CEA for Oncology - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Cyt-HiPoA - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
DB-02901 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
mepacrine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
MS-417 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
pasireotide - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
PT-112 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Recombinant Protein to Antagonize IGF-1R for Liver Metastasis and Breast Cancer - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
talimogene laherparepvec - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
TGM-002 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
TGM-003 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Hepatic (Liver) Metastasis - Recent Pipeline Updates 55
Hepatic (Liver) Metastasis - Dormant Projects 64
Hepatic (Liver) Metastasis - Discontinued Products 65
Hepatic (Liver) Metastasis - Product Development Milestones 66
Featured News & Press Releases 66
Apr 16, 2014: Cleveland BioLabs Announces the Successful Completion of a Phase 1 Study of CBL0102 66
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 67
Disclaimer 68

List of Tables

Number of Products under Development for Hepatic (Liver) Metastasis, H2 2015 9
Number of Products under Development for Hepatic (Liver) Metastasis - Comparative Analysis, H2 2015 10
Number of Products under Development by Companies, H2 2015 11
Number of Products under Investigation by Universities/Institutes, H2 2015 12
Comparative Analysis by Clinical Stage Development, H2 2015 13
Comparative Analysis by Early Stage Development, H2 2015 14
Products under Development by Companies, H2 2015 15
Products under Investigation by Universities/Institutes, H2 2015 16
Hepatic (Liver) Metastasis - Pipeline by Amgen Inc., H2 2015 17
Hepatic (Liver) Metastasis - Pipeline by BioCancell Ltd, H2 2015 18
Hepatic (Liver) Metastasis - Pipeline by CytRx Corporation, H2 2015 19
Hepatic (Liver) Metastasis - Pipeline by Digna Biotech, S.L., H2 2015 20
Hepatic (Liver) Metastasis - Pipeline by Gradalis Inc., H2 2015 21
Hepatic (Liver) Metastasis - Pipeline by Incuron, LLC, H2 2015 22
Hepatic (Liver) Metastasis - Pipeline by Novartis AG, H2 2015 23
Hepatic (Liver) Metastasis - Pipeline by Phosplatin Therapeutics LLC, H2 2015 24
Hepatic (Liver) Metastasis - Pipeline by Targetome, H2 2015 25
Assessment by Monotherapy Products, H2 2015 26
Number of Products by Stage and Target, H2 2015 28
Number of Products by Stage and Mechanism of Action, H2 2015 30
Number of Products by Stage and Route of Administration, H2 2015 32
Number of Products by Stage and Molecule Type, H2 2015 34
Hepatic (Liver) Metastasis Therapeutics - Recent Pipeline Updates, H2 2015 55
Hepatic (Liver) Metastasis - Dormant Projects, H2 2015 64
Hepatic (Liver) Metastasis - Discontinued Products, H2 2015 65